-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
-
Summary
-
InMed Pharmaceuticals Inc. quarterly and annual Revenues in USD history and change rate from 31 Dec 2021 to 31 Dec 2025.
- InMed Pharmaceuticals Inc. Revenues for the quarter ending 31 Dec 2025 was $820,188, a 26% decline year-over-year.
- InMed Pharmaceuticals Inc. Revenues for the twelve months ending 31 Dec 2025 was $4,506,597, a 6.7% decline year-over-year.
- InMed Pharmaceuticals Inc. annual Revenues for 2025 was $4,942,633, a 7.5% increase from 2024.
- InMed Pharmaceuticals Inc. annual Revenues for 2024 was $4,597,730, a 11% increase from 2023.
- InMed Pharmaceuticals Inc. annual Revenues for 2023 was $4,135,561, a 280% increase from 2022.